Overview
Tirzepatide is a dual receptor agonist, engaging both GIP and GLP-1 receptor pathways — one of the most extensively studied compounds in incretin-pathway research.
The Rexora Rexora Tirzepatide 40mg pen supplies this compound pre-filled at a fixed concentration, removing the reconstitution step required with a lyophilised vial. Nova Biolabs supplies it from UK domestic stock.
Key Research Areas
GIP/GLP-1 Pathway Research
Simultaneous engagement of both incretin receptor pathways makes Tirzepatide a widely-used tool for studying combined-pathway metabolic signalling.
Insulin Sensitivity Studies
Its dual-agonist profile is frequently used in research examining insulin sensitivity pathways alongside appetite-regulation signalling.
Comparative Incretin Research
As one of the most studied dual agonists, Tirzepatide is often used as a reference compound in comparative incretin-pathway research.
Pre-Filled Pen Delivery Research
The Rexora pen format supplies a fixed, pre-measured dose without a separate reconstitution step, useful where dosing consistency across research sessions matters.
Product Specifications
| Format | Pre-filled pen, ready to use |
| Content | 40mg Tirzepatide |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Do not freeze. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |